Szemészet, 2015 (152. évfolyam, 1-4. szám)
2015-12-01 / 4. szám
Biologie agents in ophthalmology 8. Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis. J Rheumatol Jan 2013; 40 (1): 74-79. 9. Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 2013; 11 (1): 16. 10. Diaz-Lopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: prospective multicenter study of 131 patients. Ophthalmology 2012; 119 (8): 1575-1581. 11. Miserocchi E, Pontikaki I, Modorati G, et al. Rituximab for uveitis. Ophthalmology 2011; 118 (1): 223-224. 12. Heiligenhaus A, Miserocchi E, Heinz C, et al Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab] Rheumatology 2011; 50 (8): 1390-1394. 13. Myers AC, et al. Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab. Curr Eye Res 2014 Nov; 39(11): 1106-16. 14. Ibrahim MA, Sepah YJ, Watters A, Bittencourt M, Vigil EM, Do DV, Nguyen QD. One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for Uveitis. Transl Vis Sei Technoi 2015 Mar 10; 4 (2): 4. 15. Papo M, Bielefeld R Vallet H, Seve R et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014 Jul-Aug; 32 (4 Suppl 84): S75-9. 16. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug Br J Ophthalmol 2012; 96 (9): 1157-1158. 17. Poor Gy. A reumatológia tankönyve Medicina Könyvkiadó; 2008. 18. Daniel É Martin, Maureen G. Maguire, Stuart L. Fine, et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results. Ophthalmology 2012 Jut 119 (7): 1388-1398. 19. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444. 20. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. 21. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72. 22. The Diabetic Retinopathy Clinical Research Network Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med 2015 Mar 26; 372(13): 1193-1203. 23. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-7. 24. Mitchell R Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-25. 25. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117: 1078-86. 26. Arevalo JE Lasave AF Wu L, et al. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-American Collaborative Retina Study Group at 24 months. Retina 2013; 33: 403-13. 27. Korobelnik JE Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247-54. 17. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-22. 28. Taiichi Hikichi, Makoto Higuchi, Takuro Matsushita, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2014; 98 (2): 195-199. □r. Szepessy Zsuzsanna, E-mail: szepzsu@yahoo.com TROPHOSAN Visiobalance Időskori makuladegenerációs betegek étrendjének kiegészítésére Forgalmazó: Dr. Kocsis & Hoffmann Pharma Kft. 1024 Budapest, Retek utca 32.; Tel.: +361 438 0257; e-mail: drkh@drkh.hu; www.trophosan.hu Gyártó: Protina Pharm. GmbH 85737 Ismaning, Ada Iperostrasse 37. Németország Notifikáeiós szám: T/1968/2015. Kapható a gyógyszertárakban és a fitotékákban. Speciális - gyógyásza Már kapható az AREDS 2 tanulmány szerinti formulában is! A napi 2x2, azaz a 4 kapszula összetétele összehasonlítva az AREDS 2 formulával: Speciális - gyógyászati célra szánt - tápszer A TROPHOSAN Visiobalance kapható havi ill. 3 havi kiszerelésben. / C-vitamin 500 mg / E-vitamin 400 IU / cink (oxid) 80 mg / réz (citrát) 2 mg / zeaxanthin 2 mg / lutein 10 mg
